CVRdatabase
Menu

Aïda Oncology ApS

Private limited companyCVR 42246468København NActive

Aïda Oncology ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2021. Equity was negative at the end of 2025 (−DKK 10.7m). The company made a loss in both 2024 and 2025, most recently DKK 5.6m. 8 other companies in the database are registered at the same address.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 1.9m+20.6% vs. 2024
Net profit−DKK 5.6m−113.5% vs. 2024
Equity−DKK 10.7m−109% vs. 2024
Employees5latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 2.6m to DKK 5.6m (2024 → 2025).

Registrations, last 24 months

  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
  • 15/11/2024: Moved to Ole Maaløes Vej 3, 2200 København N

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2021–2025 · amounts in DKK thousand

Equity and net profit

−DKK 12m−DKK 10m−DKK 8m−DKK 6m−DKK 4m−DKK 2mDKK 020212022202320242025
EquityNet profit
Financial figures for Aïda Oncology ApS
20212022202320242025Change
Revenue00not statednot statednot stated–
Gross profit–−179−2,169−2,409−1,914+20.6%
Operating profit (EBIT)−5−179−2,360−3,388−4,971−46.7%
Profit before tax–−180−2,360−3,477−6,241−79.5%
Net profit−5−180−2,360−2,613−5,580−113.5%
Total assets3511,7299,8558,344−15.3%
Equity35−145−2,505−5,118−10,698−109%
Liabilities–1464,23314,97319,042+27.2%
Cash and cash equivalents3511,7298,0516,563−18.5%
Average number of employees––125+150%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 2.5m−DKK 2m−DKK 1.5m−DKK 1m−DKK 500kDKK 0DKK 500kDKK 1m20212022202320242025
Gross profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 10.7m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 5 years in a row

    Net result has been negative in 2021–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

5 financial years
Annual reports for Aïda Oncology ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202502/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202403/07/2025The companyPDF not statedXBRL
202301/01/2023 – 31/12/202310/07/2024The companyPDFXBRL
202201/01/2022 – 31/12/202214/07/2023The companyPDF not statedXBRL
202123/03/2021 – 31/12/202114/07/2022The companyPDF not statedXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
012345608/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Gross profit−DKK 1.9mNo. 344 of 421
Better than 18% of the companies in the industry
Equity−DKK 10.7mNo. 403 of 431
Better than 7% of the companies in the industry
Number of employees5No. 203 of 431
Better than 53% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,162of 69,742
Better than 1%
No. 69,612of 69,964
Better than 1%
Same industry and fewer than 20 employees329 companies in the comparison
No. 265of 323
Better than 18%
No. 312of 329
Better than 5%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,280of 33,588
Better than 1%
No. 33,375of 33,687
Better than 1%
All companies of type ApS66,508 companies in the comparison
No. 65,912of 66,379
Better than 1%
No. 66,154of 66,505
Better than 1%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Aïda Oncology ApS−DKK 1.9m
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Aïda Oncology ApS−DKK 5.6m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Aïda Oncology ApS−DKK 10.7m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Aïda Oncology ApS5
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Buhl Krone Holding ApS50%
  • Arrow Strategy Holding 2 ApS15%
  • 1632 Llp25%
  • Ida Kappel Buhl5%
Aïda Oncology ApS

Management

6 active registrations

Executive management

Executive management at Aïda Oncology ApS
NameRoleAppointed
Claus Frisenberg PedersenDirector23/03/2021
Ulla Hald BuhlCEO01/03/2022

Board of directors

Board of directors at Aïda Oncology ApS
NameRoleAppointed
Claus Frisenberg PedersenBoard member01/03/2024
Neil GoldsmithChair of the board01/03/2024
Peter BuhlBoard member01/03/2024
Ulla Hald BuhlBoard member01/03/2024
Founders
Buhl Krone Holding ApS, Arrow Strategy Holding 2 ApS, 1632 Llp

Signing rule: Virksomheden tegnes af den administrerende direktør i forening med 1 bestyrelsesmedlem, eller af alle bestyrelsesmedlemmer i forening

Address and production units

1 active production units

Ole Maaløes Vej 3
2200 København N

København Municipality · Postcode 2200

Other companies at the address (8)

  • BII Holdings A/SOther financial service activities n.e.c.
  • Skape Bio ApSResearch and experimental development on natural sciences and engineering
  • Agrobiomics ApSResearch and experimental development on natural sciences and engineering
  • Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
  • BioColor ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
AÏDA ONCOLOGY ApsOle Maaløes Vej 3, 2200 København N51026950933

Purpose

Virksomhedens formål er at udvikle og kommercialisere produkter og services relateret til behandling af kræft

The purpose is quoted from the register in Danish.

Changes year by year

20 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20252 changesaccounts 1 · industry 1
  • Annual report for 2024 published
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20246 changesaddress 1 · accounts 1 · management 4
  • Moved to Ole Maaløes Vej 3, 2200 København N
  • Annual report for 2023 published
  • Claus Frisenberg Pedersen appointed board member
  • Neil Goldsmith appointed chair of the board
  • Peter Buhl appointed board member
  • Ulla Hald Buhl appointed board member
20234 changesaddress 2 · ownership 1 · accounts 1
  • Moved to Deventergade 4, 2791 Dragør
  • Ida Kappel Buhl registered as owner (5%)
  • Annual report for 2022 published
  • Moved to Skovhegnet 9, 3460 Birkerød
20222 changesaccounts 1 · management 1
  • Annual report for 2021 published
  • Ulla Hald Buhl appointed ceo
20215 changesfounded 1 · management 1 · ownership 3
  • Registered as AÏDA ONCOLOGY Aps
  • Claus Frisenberg Pedersen appointed director
  • BUHL KRONE HOLDING ApS registered as owner (50%)
  • Arrow Strategy Holding 2 ApS registered as owner (15%)
  • 1632 LLP registered as owner (25%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction